The role of high-dose melphalan with autologous stem-cell transplant in multiple myeloma: is it time for a paradigm shift?

ABSTRACT: Recent advances in multiple myeloma include numerous approvals of novel therapies with unprecedented efficacy, a rapid and sustained tempo of new drug development, and further refinements to prognostication to include minimal residual disease (MRD) testing and improved risk stratification. The upfront use of immunomodulatory drug and proteasome inhibitor combinations followed by maintenance has resulted in transformative clinical benefit. Four-drug regimens incorporating monoclonal antibodies are reporting unprecedented rates of complete response and MRD negativity in the absence of intensification. In the context of these advances, the added value of high-dose melphalan with autologous stem-cell transplant (HDM-ASCT) is a key question. From a safety standpoint, HDM-ASCT is associated with

SUBMITTER: Kazandjian D 

PROVIDER: S-EPMC8505046 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature